Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020136603 - USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING ATHEROSCLEROSIS

Publication Number WO/2020/136603
Publication Date 02.07.2020
International Application No. PCT/IB2019/061377
International Filing Date 26.12.2019
IPC
C07K 16/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Applicants
  • NEURACLE SCIENCE CO., LTD. [KR]/[KR]
Inventors
  • KIM, Bongcheol
  • KIM, Dong Sik
  • LEE, Jae-Keun
  • SHIM, Juwon
Priority Data
62/785,56927.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING ATHEROSCLEROSIS
(FR) UTILISATION D'ANTICORPS ANTI-FAM19A5 POUR LE TRAITEMENT DE L’ATHÉROSCLÉROSE
Abstract
(EN)
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
(FR)
La présente invention concerne l'utilisation pharmaceutique d'antagonistes (par exemple, un anticorps ou une partie de liaison à l'antigène de celui-ci) qui se lient de manière spécifique à FAM19A5 pour traiter une athérosclérose chez un sujet en ayant besoin.
Also published as
Latest bibliographic data on file with the International Bureau